SpringerLink
Log in

Lipidomics as a Tool for the Study of Lipoprotein Metabolism

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Although technologies for lipidomic and proteomic investigations have developed very recently, lipidomic and proteomic studies of plasma lipoproteins have already provided several impressive examples of detailed characterization of distinct metabolic pathways potentially involved in lipoprotein metabolism in both health and disease states (obesity, insulin resistance, fatty liver disease) as well as under lifestyle and dietary modification (fish consumption, carbohydrates, probiotics) and lipid-modifying treatments (statins, low-density lipoprotein apheresis). Available lipidomic methodologies have facilitated detailed characterization of lipid classes and molecular species present in plasma as well as in lipoprotein fractions. Together with emerging proteomic techniques, lipidomics of plasma lipoproteins will soon provide molecular details of lipoprotein composition, which will ultimately be translated into integrated knowledge of the structure, metabolism, and function of lipoproteins in health and disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Vaisar T: Thematic Review Series: Proteomics. Proteomic analysis of lipid-protein complexes. J Lipid Res 2009, 50:781–786.

    Article  CAS  PubMed  Google Scholar 

  2. Hoofnagle AN, Heinecke JW: Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J Lipid Res 2009, 50:1967–1975.

    Article  CAS  PubMed  Google Scholar 

  3. Davidsson P, Hulthe J, Fagerberg B, Camejo G: Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010, 30:156–163.

    Article  CAS  PubMed  Google Scholar 

  4. Oresic M, Hanninen VA, Vidal-Puig A: Lipidomics: a new window to biomedical frontiers. Trends Biotechnol 2008, 26:647–652.

    Article  CAS  PubMed  Google Scholar 

  5. Seppanen-Laakso T, Oresic M: How to study lipidomes. J Mol Endocrinol 2009, 42:185–190.

    Article  CAS  PubMed  Google Scholar 

  6. • Wiesner P, Leidl K, Boettcher A, et al.: Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009, 50:574–585. This is a pioneering study of the lipidomics of isolated plasma lipoproteins (VLDL, LDL, HDL).

    Article  CAS  PubMed  Google Scholar 

  7. Sysi-Aho M, Vehtari A, Velagapudi VR, et al.: Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles. Bioinformatics 2007, 23:i519–528.

    Article  CAS  PubMed  Google Scholar 

  8. • Kontush A, Therond P, Zerrad A, et al.: Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007, 27:1843–1849. This is a pioneering study of the lipidome of isolated lipoprotein subclasses (HDL2b, 2a, 3a, 3b, 3c).

    Article  CAS  PubMed  Google Scholar 

  9. Hansel B, Giral P, Nobecourt E, et al.: Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004, 89:4963–4971.

    Article  CAS  PubMed  Google Scholar 

  10. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881–1888.

    Article  CAS  PubMed  Google Scholar 

  11. Nilsson A, Duan RD: Absorption and lipoprotein transport of sphingomyelin. J Lipid Res 2006, 47:154–171.

    Article  CAS  PubMed  Google Scholar 

  12. Duong PT, Collins HL, Nickel M, et al.: Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I. J Lipid Res 2006, 47:832–843.

    Article  CAS  PubMed  Google Scholar 

  13. Nakamura Y, Kotite L, Gan Y, et al.: Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase. Biochemistry 2004, 43:14811–14820.

    Article  CAS  PubMed  Google Scholar 

  14. Subbaiah PV, Liu M: Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. J Biol Chem 1993, 268:20156–20163.

    CAS  PubMed  Google Scholar 

  15. Asztalos B, Zhang W, Roheim PS, Wong L: Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alpha-migrating high-density lipoprotein particles. Arterioscler Thromb Vasc Biol 1997, 17:1630–1636.

    CAS  PubMed  Google Scholar 

  16. de Souza JA, Vindis C, Negre-Salvayre A, et al.: Small, dense HDL3 particles attenuates apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 2009 (in press).

  17. Catalano G, Julia Z, Frisdal E, et al.: Torcetrapib differentially modulates the biological activities of hdl2 and hdl3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009, 29:268–275.

    Article  CAS  PubMed  Google Scholar 

  18. Zerrad-Saadi A, Therond P, Chantepie S, et al.: HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of Apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2009, 29:2169–2175.

    Article  CAS  PubMed  Google Scholar 

  19. Taylor AJ, Villines TC, Stanek EJ, et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113–2122.

    Article  CAS  PubMed  Google Scholar 

  20. Kontush A, Guerin M, Chapman MJ: Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008, 5:329–336.

    Article  CAS  PubMed  Google Scholar 

  21. • Pietilainen KH, Sysi-Aho M, Rissanen A, et al.: Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects—a monozygotic twin study. PLoS One 2007, 2:e218. This is an elegant demonstration of specific alterations in the serum lipidome in acquired obesity.

    Article  PubMed  Google Scholar 

  22. de Mello VD, Lankinen M, Schwab U, et al.: Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 2009, 52:2612–2615.

    Article  CAS  PubMed  Google Scholar 

  23. Kotronen A, Seppanen-Laakso T, Westerbacka J, et al.: Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring) 2009 (in press).

  24. • Kotronen A, Velagapudi VR, Yetukuri L, et al.: Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 2009, 52:684–690. This is an excellent lipidomics-based detailing of the relationship between insulin resistance and circulating TG levels.

    Article  CAS  PubMed  Google Scholar 

  25. Puri P, Wiest MM, Cheung O, et al.: The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009, 50:1827–1838.

    Article  CAS  PubMed  Google Scholar 

  26. Kotronen A, Seppanen-Laakso T, Westerbacka J, et al.: Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009, 58:203–208.

    Article  CAS  PubMed  Google Scholar 

  27. Kolak M, Westerbacka J, Velagapudi VR, et al.: Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007, 56:1960–1968.

    Article  CAS  PubMed  Google Scholar 

  28. Yetukuri L, Katajamaa M, Medina-Gomez G, et al.: Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol 2007, 1:12.

    Article  PubMed  Google Scholar 

  29. • Graessler J, Schwudke D, Schwarz PE, Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 2009, 4:e6261. This is the first demonstration of abnormalities in the plasma lipidome in hypertension.

    Article  PubMed  Google Scholar 

  30. • Guerrera IC, Astarita G, Jais JP, et al.: A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. PLoS One 2009, 4:e7735. This is the first demonstration of abnormalities in the plasma lipidome in cystic fibrosis.

    Article  PubMed  Google Scholar 

  31. Schwab U, Seppanen-Laakso T, Yetukuri L, et al.: Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism—the GENOBIN study. PLoS One 2008, 3:e2630.

    Article  PubMed  Google Scholar 

  32. Lankinen M, Schwab U, Erkkila A, et al.: Fatty fish intake decreases lipids related to inflammation and insulin signaling—a lipidomics approach. PLoS One 2009, 4:e5258.

    Article  PubMed  Google Scholar 

  33. Lankinen M, Schwab U, Gopalacharyulu PV, et al.: Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2009 (in press).

  34. Kekkonen RA, Sysi-Aho M, Seppanen-Laakso T, et al.: Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J Gastroenterol 2008, 14:3188–3194.

    Article  PubMed  Google Scholar 

  35. Altmaier E, Kastenmuller G, Romisch-Margl W, et al.: Variation in the human lipidome associated with coffee consumption as revealed by quantitative targeted metabolomics. Mol Nutr Food Res 2009, 53:1357–1365.

    Article  CAS  PubMed  Google Scholar 

  36. • Bergheanu SC, Reijmers T, Zwinderman AH, et al.: Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin 2008, 24:2477–2487. This is a pioneering study of the differential effects of rosuvastatin and atorvastatin on the plasma lipidome, notably on the SM/(SM+PC) ratio.

    Article  CAS  PubMed  Google Scholar 

  37. Jiang XC, Paultre F, Pearson TA, et al.: Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000, 20:2614–2618.

    CAS  PubMed  Google Scholar 

  38. Laaksonen R, Katajamaa M, Paiva H, et al.: A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 2006, 1:e97.

    Article  PubMed  Google Scholar 

  39. Laaksonen R, Janis MT, Oresic M: Lipidomics-based safety biomarkers for lipid-lowering treatments. Angiology 2008, 59(2 Suppl):65S–68S.

    Article  PubMed  Google Scholar 

  40. Tselmin S, Schmitz G, Julius U, et al.: Acute effects of lipid apheresis on human serum lipidome. Atheroscler Suppl 2009, 10:27.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

These studies were supported by the National Institute for Health and Medical Research (INSERM), University of Pierre and Marie Curie (UPMC), CODDIM Ile-de-France, the Fondation de France and the Fondation pour la Recherche Médicale (Paris, France). AK acknowledges the award of a Contrat d’Interface from Assistance Publique—Hôpitaux de Paris/INSERM (France).

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Université Pierre et Marie Curie-Paris 6, Paris, 75013, France

    Anatol Kontush & M. John Chapman

  2. AP-HP, Groupe hospitalier Pitié-Salpétrière, Paris, 75013, France

    Anatol Kontush & M. John Chapman

  3. Dyslipidemia, Inflammation and Atherosclerosis Research Unit (UMR 939), National Institute for Health and Medical Research (INSERM), Paris, 75013, France

    Anatol Kontush & M. John Chapman

  4. INSERM Unit 939, Pavillon Benjamin Delessert, Hôpital de la Pitié, 83 boulevard de l’Hôpital, 75651, Paris, Cedex 13, France

    Anatol Kontush

Authors
  1. Anatol Kontush
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. John Chapman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anatol Kontush.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kontush, A., Chapman, M.J. Lipidomics as a Tool for the Study of Lipoprotein Metabolism. Curr Atheroscler Rep 12, 194–201 (2010). https://doi.org/10.1007/s11883-010-0100-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-010-0100-0

Keywords

Search

Navigation